Brand Name
Mavyret
Generic Name
Glecaprevir
View Brand Information FDA approval date: August 03, 2017
Classification: Hepatitis C Virus NS3/4A Protease Inhibitor
Form: Pellet, Tablet
What is Mavyret (Glecaprevir)?
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis . MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor , but not both [see Dosage and Administration.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Randomized Controlled Trial of Glecaprevir/Pibrentasvir for the Treatment of Post-traumatic Stress Disorder
Summary: A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).
The Study of Hepatitis Eradication Receiving Protease Inhibitor Administration
Summary: This is a prospective, non-blinded cohort study that will assess the safety, tolerability, and antiviral efficacy of glecaprevir/pibrentasivir therapy given post-discharge to HCV-negative recipients of HCV infected donors. Patients who meet entry criteria will be enrolled while on the transplant waitlist. At the time of transplant, some donors will be HCV positive / NAT positive and some will not ...